OFFICIAL LEGAL TITLE
Combating Counterfeit Pharmaceuticals Act of 2025
FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 119_S_3134.
Which chamber initiated this legislation?
This legislation was initiated in the Senate.
When did the legislative process begin?
The process officially started on 2025-11-06.
What are the main provisions?
Key points include:
- The government's power to impose sanctions now targets foreign traffickers of all illicit drugs, counterfeit drugs, and imitation ingredients, moving beyond the previous focus on opioids.
- New definitions are introduced to specifically combat "copy-cat ingredients"—substances mimicking approved prescription drugs but failing quality standards—aiming to protect consumers from dangerous fakes.
- Waivers allowing access to prescription medications despite sanctions are now strictly limited to drugs officially listed as being in short supply by the Secretary of Health and Human Services.
What is the specific legal status?
The current status is Introduced.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Sen. Cotton, Tom [R-AR].
What is the latest detailed status?
The latest detailed status is: Introduced in Senate
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.
What is the impact of this bill?
We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.